CTRI/2026/07/114164进行中（未招募）不适用
A Randomized placebo controlled study to know effectiveness of homeopathy in the symptomatic management of varicose veins with physiotherapy - NIL
Ahmedabad Homoeopathic Medical College attached to Sainath Hospital0 个研究点目标入组 60 人开始时间: 2026年7月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adults aged 35 to 65 years. Both males and females. Patients willing to give informed written consent.
排除标准
- •Pregnant or lactating women. Patients with deep vein thrombosis, arterial disease, malignancy, or severe cardiovascular disorders. Patients already taking conventional medications for varicose veins. Terminally ill patients, congenital vascular malformations.
研究者
相似试验
已完成
1 期
Randomized, double-blind, placebo-controlled study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of pitolisant after repeated oral ascending doses for 14 days, including the pitolisant effect on cardiac repolarization in healthy volunteers.2023-503945-78-00Bioprojet Pharma75
招募中
1 期
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain2025-523737-26-00Centrexion Therapeutics Corp.20
招募中
1 期
A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patientsAcute Incomplete Cervical Spinal Cord Injury2026-526089-26-00NovaGo Therapeutics AG84
招募中
1 期
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease2025-522582-30-00Alnylam Pharmaceuticals Inc.7
招募中
不适用
Phase 3 study of secutrelvir in participants with COVID-19 who are at high risk for progression to severe disease (COVID-19)COVID-19jRCT20712600722,000